Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

125.14 -12.30 (-8.95%)
Streaming Delayed Price Updated: 11:54 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
News headline image
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
News headline image
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
NASDAQ:NBIX: good value for what you're paying. ↗
Investors should take notice ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
Neurocrine Biosciences Stock Sees RS Rating Upgrade ↗
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
Via Investor's Business Daily
News headline image
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable. ↗
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
What Analysts Are Saying About Neurocrine Biosciences Stock ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX qualifies as a high growth stock and is consolidating. ↗
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
News headline image
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
News headline image
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
News headline image
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential ↗
Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation. 
Via Benzinga
News headline image
Neurocrine Wins FDA Approval For Genetic Disorder Drug ↗
The company can launch within a week, says Chief Executive Kyle Gano. 
Via Investor's Business Daily
News headline image
Screening For Black Friday Bargains In The Stock Market ↗
 
Via Benzinga
News headline image
Decoding 19 Analyst Evaluations For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX, a growth stock which is not overvalued. ↗
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. 
Via Chartmill
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio ↗
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga
News headline image
In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. 
Via Chartmill
News headline image
NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins ↗
Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off. 
Via The Motley Fool
News headline image
Despite its growth, NASDAQ:NBIX remains within the realm of affordability. ↗
In the world of growth stocks, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) shines as a value proposition. 
Via Chartmill
News headline image
For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint ↗
Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in treating cognitive impairment in schizophrenia. The company will halt development... 
Via Benzinga
News headline image
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio? ↗
10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences. 
Via Benzinga
News headline image
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS